Targeting TRPV6/CXCR4 complexes prevents castration-resistant prostate cancer metastasis to the bone

Area of Science:

• Oncology
• Molecular Biology
• Calcium Channel Research

Background:

• Castration-resistant prostate cancer (CRPC) frequently metastasizes to bone.
• TRPV6 calcium channel expression is upregulated in prostate cancer and absent in healthy tissue.
• TRPV6 may facilitate cancer cell adaptation to bone microenvironment and promote metastasis.

Purpose of the Study:

• To investigate the role of TRPV6 in CRPC aggressiveness and bone metastasis.
• To elucidate the molecular mechanisms by which TRPV6 promotes invasion and metastasis.
• To evaluate the therapeutic potential of targeting TRPV6 and CXCR4 in CRPC.

Main Methods:

• Analysis of patient tissue biopsies correlating TRPV6 expression with CRPC aggressiveness and metastasis.
• In vitro studies on cellular phenotypes, signaling pathways (CaMK2, NF-κB), and marker expression (EMT, MMPs).
• In vivo studies using trpv6 knockout mice and xenograft models; therapeutic interventions with anti-TRPV6 antibody and CXCR4 inhibitor (AMD3100).

Main Results:

• TRPV6 expression positively correlates with CRPC tumor aggressiveness and metastasis risk.
• TRPV6 promotes mesenchymal and invasive phenotypes via CaMK2/NF-κB signaling and EMT marker upregulation.
• TRPV6 forms complexes with CXCR4, enhancing metastasis; dual targeting of TRPV6 and CXCR4 synergistically inhibits metastasis in vivo.

Conclusions:

• TRPV6 is a key driver of CRPC bone metastasis by facilitating cellular invasion and adaptation.
• The TRPV6/CXCR4 axis represents a critical pathway for CRPC progression.
• Combined targeting of TRPV6 and CXCR4 demonstrates a promising therapeutic strategy for suppressing CRPC metastasis.